Skip to main content

Table 1 Patient characteristics and tumor size pre- and post-125I seed implantation in the 22 patients

From: Palliative treatment of pelvic bone tumors using radioiodine (125I) brachytherapy

    

Pre-implantation tumor characteristics

Post-implantation (1 month) tumor characteristics

Gender

Age

Pathological type

Dose (cGy)

Major axis (cm)

Minor axis (cm)

Volume (cm3)

Major axis (cm)

Minor axis (cm)

Volume (cm3)

M

34

Chordoma

80

16.7

10.2

839.2

14.5

9.1

604.65

M

58

Chordoma

30

10.1

7.9

314.7

6.6

5.2

88

M

58

Chordoma

100

22

14.4

2288

22

14.6

2346.3*

M

84

Chordoma

100

19.1

12.3

1441.7

14.8

11.8

1025.64

F

43

Chordoma

50

8

3.7

54.4

7

3.3

39.2

F

47

Chordoma

30

13.3

6.3

267.9

12.1

4.9

148.1

M

20

GCT

20

8.9

5.6

142

8

5.1

111

M

30

GCT

100

20

11.6

1350

18

9.2

768.6

F

64

GCT

60

6

4.7

67.5

5.8

4

46.4

M

75

Osteosarcoma

70

9.8

3.9

76.3

9.7

3.5

60.5

F

15

Osteosarcoma

80

18

9.6

828

14.7

8.9

582.12

F

20

Osteosarcoma

60

15.6

9.4

683.3

9.7

8.1

494.7

M

39

Chondrosarcoma

30

10.3

6.9

248

9.1

6.1

168

M

46

Chondrosarcoma

20

9.3

6.5

195.3

6.6

5.7

107.1

M

54

Fibrosarcoma

100

20.9

12.7

1681.6

19.7

12

1427.3

F

60

Fibrosarcoma

40

14.4

8.1

474.2

15.3

8.3

523.3*

F

24

Malignant melanoma

30

10.7

7.4

293.9

10

6.5

209

F

50

Malignant melanoma

30

10

7.7

368

9.5

7.5

267

M

39

B-DLCL

20

8.5

5.8

142.8

3.8

2.7

13.4

F

44

Hemangioma

10

7.4

4.6

79.5

6.5

3.9

50.7

M

61

Leiomyosarcoma

100

14.7

12.1

1070

15

13.1

1300.7*

F

16

Mesenchymal neoplasm

10

7.8

3.6

49.2

7.2

3.1

34

n = 22 Median (IQR)

45 (27.5–85.0)

10.5 (8.8–17.0)

7.55 (5.4–10.6)

304.3 (126.4–896.9)

9.7 (6.9–14.9)

6.3 (4.0–9.1)

188.5 (58.05–645.6)

  1. *Tumor progression